A Study to Evaluate a New Treatment for Cancer
Phase 1/2
474
about 5.2 years
18+
12 sites in AZ, CA, FL +6
What this study is about
This trial is testing a new treatment, called A2B543 and A2B694, in people with solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression. The goal is to determine if the treatment is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive A2B543
- 2.Receive A2B694
- 3.XT CDx with HLA-LOH Assay
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level, Phase 2: The Overall Response Rate (ORR) for patients
Secondary: Cytokine analysis
diagnostic
Oncology, Gastroenterology